Managed Account Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Managed Account Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$147K	Sell	7,753 -831	-10%	-$18K	﹤0.01%	2543
2015 Q1	$225K	Buy	+8,584	New	+$218K	﹤0.01%	2409
2014 Q4	–	Sell	-76,949	Closed	-$2.57M	–	2817
2014 Q3	$2.57M	Sell	76,949 -36,373	-32%	-$1.13M	﹤0.01%	1708
2014 Q2	$3.64M	Buy	113,322 +16,768	+17%	+$624K	﹤0.01%	1528
2014 Q1	$4.46M	Buy	96,554 +19,136	+25%	+$1.12M	0.01%	1379
2013 Q4	$5.49M	Buy	77,418 +29,407	+61%	+$2.25M	0.01%	1252
2013 Q3	$4.12M	Buy	48,011 +23,599	+97%	+$2M	0.01%	1329
2013 Q2	$1.55M	Buy	+24,412	New	+$1.3M	﹤0.01%	1717

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Managed Account Advisors's AEGR Position: Q2 2015 in Review

Managed Account Advisors reduced its Aegerion Pharmaceuticals (AEGR) stake by 9.7% in Q2 2015, selling an estimated $18K and leaving 7,753 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #2543.

Managed Account Advisors first reported a position in AEGR in Q2 2013 and has held it in 8 quarters since. The position peaked at $5.49M in Q4 2013. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

Managed Account Advisors held 7,753 shares of Aegerion Pharmaceuticals worth $147K as of Q2 2015.
Managed Account Advisors sold 831 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $18K.
Aegerion Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2543 holding.
Managed Account Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
Managed Account Advisors's Aegerion Pharmaceuticals position peaked at $5.49M in Q4 2013.
97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.